Armata Pharmaceuticals
Update in progressARMP (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies to address antibiotic‑resistant infections worldwide. Using its proprietary phage technology, it advances candidates such as AP‑SA02 for Staphylococcus aureus bacteremia and AP‑PA03 for Pseudomonas aeruginosa. Headquartered in Los Angeles, Armata operates as a subsidiary of Innoviva, Inc.
Company score
- Sentiment
- 0.38
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.23
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!